The hope is that subsequent medications will have fewer side effects
We have to look at patients holistically, who have kidney disease and diabetes, to address the totality of risks, certainly progression to kidney failure, but also prevention of cardiovascular events and deaths. Ozempic and other GLP-1s will be compared to another diabetes drug class, SGLT-2 inhibitors Given Ozempics reduction of kidney disease events in the FLOW study, it seems likely that the GLP-1s will be used together with and compared against SGLT-2 inhibitor drugs
They're being talked about all the time, as am I, and they're changing how we think about weight management, fat loss, lifestyle combined with these drugs, understanding alternatives, and it's really cool to have something that might work through similar pathways
Vitamins and minerals - Iron
The medication produces a range of effects on the body, and knowing which are common versus rare helps calibrate concern appropriately